Is it safe for a woman of child‑bearing age who is planning pregnancy to continue citalopram, or should she switch to sertraline or taper the medication before conception?

Citalopram and Conception

Women planning pregnancy who are stable on citalopram should generally continue their medication rather than discontinue or switch, as the risks of untreated depression during pregnancy outweigh the minimal teratogenic risks associated with citalopram use.

Clinical Decision Framework

The decision to continue, switch, or discontinue citalopram before conception should be based on:

1. Severity and Stability of Depression

Continue citalopram if:

• The patient has moderate-to-severe depression
• History of severe relapse when discontinuing antidepressants
• Previous suicide attempts or severe depression episodes
• Current medication provides good symptom control with minimal side effects

The FDA label explicitly states that "women who discontinued antidepressant medication during pregnancy showed a significant increase in relapse of their major depression compared to those women who remained on antidepressant medication throughout pregnancy" 1. A 2025 study confirmed that women who discontinued antidepressant treatment during pregnancy had significantly higher rates of pregnancy depression (p=0.01) and postpartum depression (p<0.0001) compared to those who continued treatment 2.

Consider discontinuation only if:

• Mild depression with recent onset (≤2 weeks)
• Patient has been stable and symptom-free for an extended period
• Strong patient preference after thorough risk-benefit discussion
• Access to intensive psychotherapy as alternative treatment 3

2. Switching to Sertraline: Not Routinely Recommended

There is no compelling evidence to routinely switch from citalopram to sertraline before conception. Both medications have similar safety profiles during pregnancy:

• A 2017 systematic review concluded that "sertraline and citalopram should be first-line drug treatments for anxiety and depression in pregnant women in the SSRI class" 4
• Both drugs show minimal and generally unsubstantiated associations with negative outcomes when controlled for maternal depression 4
• A 2023 Dutch study found that switching rates between antidepressants during pregnancy remained consistently low (2.0-2.3%), indicating that "pregnant women prefer to continue their prepregnancy medication rather than switch it" 5

Switching may introduce unnecessary risks:

• Loss of therapeutic efficacy during the transition period
• Potential for symptom relapse during medication adjustment
• No clear safety advantage of sertraline over citalopram

3. Understanding the Actual Risks

Teratogenic Risk: The FDA label states citalopram is Pregnancy Category C, meaning "there are no adequate and well-controlled studies in pregnant women" 1. However, available evidence is reassuring:

• A 2005 prospective study of 132 women exposed to citalopram found only 1 major malformation (0.9%) among 108 live births, with "citalopram use during the period of embryogenesis in pregnancy is not associated with an apparent major teratogenic risk" 6
• A 2002 study of 11 mothers found "uncomplicated pregnancy outcome in mothers using citalopram during pregnancy" with normal neurodevelopment up to 1 year 7

Neonatal Adaptation: The primary concern is poor neonatal adaptation syndrome (PNAS), not major malformations:

• Third-trimester SSRI exposure can cause transient neonatal symptoms including respiratory distress, jitteriness, feeding difficulty, and irritability 8
• These symptoms typically resolve within 1-2 weeks 8
• The 2005 study found a relative risk of 4.2 for special-care nursery admission in citalopram-exposed neonates 6
• Critically, the AAP guideline states: "SSRI treatment should be continued during pregnancy at the lowest effective dose, because withdrawal of medication may have harmful effects on the mother-infant dyad" 8

Long-term Neurodevelopment: The AAP guideline notes that "several recent reviews have not identified adverse neurodevelopmental outcomes among infants born to women treated with SSRIs during pregnancy" 8.

Practical Management Algorithm

Preconception (Current Phase):

1. Assess depression severity and treatment history

   • If severe or history of relapse: Continue citalopram
   • If mild and stable: Consider trial discontinuation with close monitoring

2. Optimize dosing

   • Use the lowest effective dose that maintains symptom control 8, 1
   • Document current dose and symptom stability

3. Patient counseling

   • Discuss that untreated depression poses greater risks than medication exposure
   • Explain PNAS is transient and manageable
   • Address that switching medications offers no clear safety advantage

During Pregnancy:

1. Continue current effective dose unless sedation or other side effects emerge 1
2. Monitor for symptom relapse - may need dose adjustment as pregnancy progresses
3. Coordinate with obstetrics for neonatal monitoring plan at delivery

Postpartum:

1. Continue citalopram - critical period for relapse prevention
2. Breastfeeding is compatible - citalopram is excreted in breast milk but infant plasma levels are very low or undetectable 7
3. Monitor infant for excessive somnolence or feeding difficulties (rare) 1

Common Pitfalls to Avoid

• Do not discontinue medication solely due to pregnancy planning - this significantly increases relapse risk 1, 2
• Do not switch medications without clear indication - introduces instability without proven benefit 5
• Do not use paroxetine - this is the one SSRI with stronger evidence of teratogenic risk and should be avoided 4, 9
• Do not forget to arrange early neonatal follow-up after delivery to monitor for PNAS 8

The evidence strongly supports continuing citalopram at the lowest effective dose through conception and pregnancy, with appropriate monitoring, rather than switching or discontinuing treatment.